Recent studies have centered on the convergence of GLP-1|GIP|glucagon receptor activator therapies and dopamine communication. While GIP activators are commonly employed for managing type 2 diabetes, their potential consequences on reinforcement circuits, specifically influenced by dopamine networks, are attracting significant focus. This article d